The general lack of the tumor-inhibitory activity of the blockers of the CTLA-4, PD-1, and HSP90 molecules in mice i.v. and o.t. injected with LLC1 cells is surprising in view of the results of studies indicating that single and especially combined applications of such blockers were able to successfully enhance the response rates and survival of patients with various malignancies including lung cancer (reviewed in [13,15,16,17,33,41]). The gene discussed is CTLA4; the disease is neoplasm.